EGFR ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS

본 발명은, 항-EGFR 항체 약물 접합체(ADC), 히스티딘, 당 및 계면활성제를 포함하는 안정한 제형을 제공하고, 상기 항-EGFR ADC는 오리스타틴, 예를 들어, MMAF에 접합된 항-EGFR 항체, 예를 들어, 항체 1을 포함한다. The invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), including an anti-EGFR antibody, e.g., antibody 1, conjugated to a...

Full description

Saved in:
Bibliographic Details
Main Authors TSCHOEPE MARKUS, KUMAR VINEET, KALETA KATHARINA
Format Patent
LanguageEnglish
Korean
Published 01.04.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:본 발명은, 항-EGFR 항체 약물 접합체(ADC), 히스티딘, 당 및 계면활성제를 포함하는 안정한 제형을 제공하고, 상기 항-EGFR ADC는 오리스타틴, 예를 들어, MMAF에 접합된 항-EGFR 항체, 예를 들어, 항체 1을 포함한다. The invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), including an anti-EGFR antibody, e.g., antibody 1, conjugated to an auristatin, e.g., MMAF, histidine, a sugar, and a surfactant.
Bibliography:Application Number: KR20227009445